SVA
Sinovac Biotech, Ltd.
Set alert
6.47 USD 0.00 0.00%
Day range unavailable
6.47 52-week range 6.47
- YTD
- 0.00%
- 1 year
- 0.00%
- Open
- —
- Prev close
- 6.47
- Mkt cap
- 642.44M
- Vol
- 0
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- —
- High
- —
- Forward P/E
- -53.92
- Beta
- 0.00
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 6.47
- 200-d avg
- 6.47
- 1y target
- 3.52
Key statistics
- Market cap
- 642.44M
- Trailing P/E
- 6.66
- Forward P/E
- -53.92
- Price / sales
- 0.00
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 0
- Total debt
- 0
- Return on equity
- 0.00%
- 50-day average
- 6.47
- 200-day average
- 6.47
Analyst view
Consensus: buy
Buy
Price target (mean) 3.52 -45.6% downside
Now 6.47
- Target (low)
- 1.50
- Target (mean)
- 3.52
- Target (high)
- 6.00
Next earnings
Consensus EPS estimate -0.03.
Financials — quick view
SVA Revenue — annual 386.01M
SVA Net income — annual -59.68M
SVA EPS — annual -0.83
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Mar 20, 2014 | Morgan Stanley | up | — | Overweight |
| Nov 13, 2013 | Aegis Capital | main | — | Buy |
| Aug 15, 2013 | Aegis Capital | up | Hold | Buy |
| May 15, 2013 | Morgan Stanley | up | Underperform | Equal-Weight |
| Mar 14, 2013 | Aegis Capital | main | — | Hold |
| Dec 12, 2012 | Aegis Capital | init | — | Hold |
News
- Sernova, Seraxis Aim for Type 1 Diabetes ‘Functional Cure’ With BetaNova Merger
- Sinovac Biotech H1 EPS $(0.84) Down From $0.06 YoY, Sales $147.079M Up From $130.270M YoY
- SINOVAC Reports Unaudited First Half of 2026 Financial Results
- SINOVAC Announces Extension of Deadline to Submit Payment Instructions for Previously Declared Special Cash Dividend
- Sinovac Biotech Regains Compliance With Nasdaq Listing Requirements
- SINOVAC Regained Compliance With the Nasdaq Global Market's Listing Requirements
- SINOVAC Reports Unaudited and Unreviewed Second Half of 2025 Financial Results and Files 2025 Annual Report on Form 20-F
- Sinovac Biotech Requests Hearing Following New Delisting Determination Related To 2025 Annual Report Filing
- SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report
- Sinovac Biotech Has Extended The Deadline For Shareholders And Nominee Brokers To Submit Payment Instructions Relating Its Previously Declared Special Cash Dividend
Your note
Sign in to keep a note on SVA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BOWERING TERRY G | Chief Executive Officer | Sale | Sep 23, 2003 | 0 |
| IFG INVESTMENTS SERVICES INC | Beneficial Owner of more than 10% of a Class of Security | Sale | Nov 3, 2003 | 0 |